IMMP IMMUTEP Ltd PDUFA2022-03-19 LAG-3 Therapeutic Landscape Overview Company Program Preclinical Phase I Phase II Phase III Total Trials Patients Eftilagimod 10 4 14 967 (5) Alpha (6) 7 32 2 BMS Relatlimab 41 9,775 Merck & Co. Inc. Favezelimab 1 5 6 1066 PDUFA goal date March 19, 2022 Ieramilimab 1 4 5 952 Macrogenics Tebotelimab 3 3 6 1422 1 2 H-L Roche RO7247669 3 538 4 1 B.I. https://www.sec.gov/Archives/edgar/data/0001506184/000119312521332807/d214596dex991.htmWhenSat 19 Mar 2022
Note extracted from FDA PDUFA calendar as above
Ann: Phase II TACTI-002 trial recruitment successfully completed, page-28
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 29.3¢ | $1.323M | 4.421M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 111754 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 61590 | 3 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |